1.Expression of Major Histocompatibility Complex during Neuronal Differentiation of Somatic Cell Nuclear Transfer-Human Embryonic Stem Cells
Jin Saem LEE ; Jeoung Eun LEE ; Shin-Hye YU ; Taehoon CHUN ; Mi-Yoon CHANG ; Dong Ryul LEE ; Chang-Hwan PARK
International Journal of Stem Cells 2024;17(1):59-69
Human pluripotent stem cells (hPSCs) such as human embryonic stem cells (hESCs), induced pluripotent stem cells, and somatic cell nuclear transfer (SCNT)-hESCs can permanently self-renew while maintaining their capacity to differentiate into any type of somatic cells, thereby serving as an important cell source for cell therapy. However, there are persistent challenges in the application of hPSCs in clinical trials, where one of the most significant is graft rejection by the patient immune system in response to human leukocyte antigen (HLA) mismatch when transplants are obtained from an allogeneic (non-self) cell source. Homozygous SCNT-hESCs (homo-SCNT-hESCs) were used to simplify the clinical application and to reduce HLA mismatch. Here, we present a xeno-free protocol that confirms the efficient generation of neural precursor cells in hPSCs and also the differentiation of dopaminergic neurons. Additionally, there was no difference when comparing the HLA expression patterns of hESC, homo-SCNT-hESCs and hetero-SCNT-hESCs. We propose that there are no differences in the differentiation capacity and HLA expression among hPSCs that can be cultured in vitro. Thus, it is expected that homo-SCNT-hESCs will possess a wider range of applications when transplanted with neural precursor cells in the context of clinical trials.
2.Bone Age Estimation and Prediction of Final Adult Height Using Deep Learning
Junghwan SUH ; Jinkyoung HEO ; Su Jin KIM ; Soyeong PARK ; Mo Kyung JUNG ; Han Saem CHOI ; Youngha CHOI ; Jun Suk OH ; Hae In LEE ; Myeongseob LEE ; Kyungchul SONG ; Ahreum KWON ; Hyun Wook CHAE ; Ho-Seong KIM
Yonsei Medical Journal 2023;64(11):679-686
Purpose:
The appropriate evaluation of height and accurate estimation of bone age are crucial for proper assessment of the growth status of a child. We developed a bone age estimation program using a deep learning algorithm and established a model to predict the final adult height of Korean children.
Materials and Methods:
A total of 1678 radiographs from 866 children, for which the interpretation results were consistent between two pediatric endocrinologists, were used to train and validate the deep learning model. The bone age estimation algorithm was based on the convolutional neural network of the deep learning system. The test set simulation was performed by a deep learning program and two raters using 150 radiographs and final height data for 100 adults.
Results:
There was a statistically significant correlation between bone age interpreted by the artificial intelligence (AI) program and the reference bone age in the test set simulation (r=0.99, p<0.001). In the test set simulation, the AI program showed a mean absolute error (MAE) of 0.59 years and a root mean squared error (RMSE) of 0.55 years, compared with reference bone age, and showed similar accuracy to that of an experienced pediatric endocrinologist (rater 1). Prediction of final adult height by the AI program showed an MAE of 4.62 cm, compared with the actual final adult height.
Conclusion
We developed a bone age estimation program based on a deep learning algorithm. The AI-derived program demonstrated high accuracy in estimating bone age and predicting the final adult height of Korean children and adolescents.
3.Metabolic Impacts of Discontinuation and Resumption of Recombinant Human Growth Hormone Treatment during the Transition Period in Patients with Childhood-Onset Growth Hormone Deficiency
Yun Jeong LEE ; Yunha CHOI ; Han-Wook YOO ; Young Ah LEE ; Choong Ho SHIN ; Han Saem CHOI ; Ho-Seong KIM ; Jae Hyun KIM ; Jung Eun MOON ; Cheol Woo KO ; Moon Bae AHN ; Byung-Kyu SUH ; Jin-Ho CHOI
Endocrinology and Metabolism 2022;37(2):359-368
Background:
Discontinuing growth hormone (GH) treatment during the transition to adulthood has been associated with adverse health outcomes in patients with childhood-onset growth hormone deficiency (CO-GHD). This study investigated the metabolic changes associated with interrupting GH treatment in adolescents with CO-GHD during the transition period.
Methods:
This study included 187 patients with CO-GHD who were confirmed to have adult GHD and were treated at six academic centers in Korea. Data on clinical parameters, including anthropometric measurements, metabolic profiles, and bone mineral density (BMD) at the end of childhood GH treatment, were collected at the time of re-evaluation for GHD and 1 year after treatment resumption.
Results:
Most patients (n=182, 97.3%) had organic GHD. The median age at treatment discontinuation and re-evaluation was 15.6 and 18.7 years, respectively. The median duration of treatment interruption was 2.8 years. During treatment discontinuation, body mass index Z-scores and total cholesterol, low-density lipoprotein, and non-high-density lipoprotein (HDL) cholesterol levels increased, whereas fasting glucose levels decreased. One year after GH treatment resumption, fasting glucose levels, HDL cholesterol levels, and femoral neck BMD increased significantly. Longer GH interruption (>2 years, 60.4%) resulted in worse lipid profiles at re-evaluation. The duration of interruption was positively correlated with fasting glucose and non-HDL cholesterol levels after adjusting for covariates.
Conclusion
GH treatment interruption during the transition period resulted in worse metabolic parameters, and a longer interruption period was correlated with poorer outcomes. GH treatment should be resumed early in patients with CO-GHD during the transition period.
4.Effect of Cannabidiol Oil on Weight Loss in Diet-Induced Obese Mice: Validation Study
Sae Saem HAN ; Shinn-Won LIM ; Sook-young WOO ; Su Jin LEE ; Doh Kwan KIM
Journal of Korean Neuropsychiatric Association 2022;61(4):281-290
Objectives:
This study aimed at investigating the pharmacological and physiological effects of cannabidiol (CBD) oil on weight loss in diet-induced obese (DIO) mice.
Methods:
A DIO mice model was constructed with 33 C57BL/6 male mice, aged six weeks, who had been fed a high-fat diet for 13 weeks. Subsequently, 20 mg/kg (n=11) or 60 mg/kg (n=11) of CBD oil or sesame seed oil (n=11) per day was given along with a high-fat diet for four weeks. The body weight of each subject was measured weekly, and venous blood was drawn for biochemistry and enzyme-linked immunoassay before and after the four-week trial period. An oral glucose tolerance test was performed to assess glucose metabolism. At the end of the CBD oil treatment, dual-energy X-ray absorptiometry was used to calculate body fat composition, and the mesenteric adipose tissue was measured as representative of the fat mass of each subject. For statistical analysis, we used the Kruskal-Wallis test, Turkey’s test using ranks and generalized estimating equations.
Results:
After administration of CBD oil (60 mg/kg) for four weeks, the DIO mice showed significant weight loss, compared to the sham control mice (p=0.027). Mice fed with 60 mg/kg of CBD oil also had a significant reduction in fat percentage (p=0.009) and mesenteric fat weight loss (p=0.024), compared to the sham control mice, even with higher food intake (p=0.029). Moreover, mice fed with 60 mg/kg of CBD oil showed a significant improvement in glucose tolerance (p=0.003) and lower plasma leptin levels (p=0.006).
Conclusion
This study shows that orally administered CBD oil induces weight loss in DIO mice. It has been postulated that CBD oil attenuates an over-activated endocannabinoid system, thereby increasing energy expenditure, and improving glucose metabolism and leptin resistance.
5.Identification of a novel point mutation in DAX-1 gene in a patient with adrenal hypoplasia congenita
Han Saem CHOI ; Ahreum KWON ; Hyun Wook CHAE ; Junghwan SUH ; Kyung Chul SONG ; Jin-Sung LEE ; Ho-Seong KIM
Annals of Pediatric Endocrinology & Metabolism 2021;26(2):126-129
X-linked adrenal hypoplasia congenita caused by a mutation in NR0B1/DAX-1 is a rare inherited disorder. Patients with adrenal hypoplasia congenita are usually diagnosed with primary adrenal insufficiency in infancy or early childhood and present hypogonadotropic hypogonadism during adolescence. Our patient first presented with adrenal crisis at the age of 2 months, which was managed with glucocorticoids and mineralocorticoids. At the age of 17 years, testicular volumes of 5 mL each and a stretched penile length of 4 cm were noted. A combined pituitary function test showed a peak luteinizing hormone level of 2.68 mIU/mL, testosterone 13.5 ng/dL, confirming hypogonadotropic hypogonadism. After whole-exome sequencing, a new variant of DAX-1, c.881T>C (p.Leu294Pro), was found. He was diagnosed with X-linked adrenal hypoplasia congenita and then treated with human choriogonadotropin for the induction of spermatogenesis as well as with steroid replacement therapy.
6.Identification of a novel point mutation in DAX-1 gene in a patient with adrenal hypoplasia congenita
Han Saem CHOI ; Ahreum KWON ; Hyun Wook CHAE ; Junghwan SUH ; Kyung Chul SONG ; Jin-Sung LEE ; Ho-Seong KIM
Annals of Pediatric Endocrinology & Metabolism 2021;26(2):126-129
X-linked adrenal hypoplasia congenita caused by a mutation in NR0B1/DAX-1 is a rare inherited disorder. Patients with adrenal hypoplasia congenita are usually diagnosed with primary adrenal insufficiency in infancy or early childhood and present hypogonadotropic hypogonadism during adolescence. Our patient first presented with adrenal crisis at the age of 2 months, which was managed with glucocorticoids and mineralocorticoids. At the age of 17 years, testicular volumes of 5 mL each and a stretched penile length of 4 cm were noted. A combined pituitary function test showed a peak luteinizing hormone level of 2.68 mIU/mL, testosterone 13.5 ng/dL, confirming hypogonadotropic hypogonadism. After whole-exome sequencing, a new variant of DAX-1, c.881T>C (p.Leu294Pro), was found. He was diagnosed with X-linked adrenal hypoplasia congenita and then treated with human choriogonadotropin for the induction of spermatogenesis as well as with steroid replacement therapy.
7.Benzydamine inhibits osteoclast differentiation and bone resorption down-regulation of interleukin-1 expression.
Han Saem SON ; Jiae LEE ; Hye In LEE ; Narae KIM ; You-Jin JO ; Gong-Rak LEE ; Seong-Eun HONG ; Minjeong KWON ; Nam Young KIM ; Hyun Jin KIM ; Jin Ha PARK ; Soo Young LEE ; Woojin JEONG
Acta Pharmaceutica Sinica B 2020;10(3):462-474
Bone diseases such as osteoporosis and periodontitis are induced by excessive osteoclastic activity, which is closely associated with inflammation. Benzydamine (BA) has been used as a cytokine-suppressive or non-steroidal anti-inflammatory drug that inhibits the production of pro-inflammatory cytokines or prostaglandins. However, its role in osteoclast differentiation and function remains unknown. Here, we explored the role of BA in regulating osteoclast differentiation and elucidated the underlying mechanism. BA inhibited osteoclast differentiation and strongly suppressed interleukin-1 (IL-1) production. BA inhibited osteoclast formation and bone resorption when added to bone marrow-derived macrophages and differentiated osteoclasts, and the inhibitory effect was reversed by IL-1 treatment. The reporter assay and the inhibitor study of IL-1 transcription suggested that BA inhibited nuclear factor-B and activator protein-1 by regulating IB kinase, extracellular signal regulated kinase and P38, resulting in the down-regulation of IL-1 expression. BA also promoted osteoblast differentiation. Furthermore, BA protected lipopolysaccharide- and ovariectomy-induced bone loss in mice, suggesting therapeutic potential against inflammation-induced bone diseases and postmenopausal osteoporosis.
8.A novel compound heterozygous mutation of the AIRE gene in a patient with autoimmune polyendocrine syndrome type 1
Junghwan SUH ; Han Saem CHOI ; Ahreum KWON ; Hyun Wook CHAE ; Jin Sung LEE ; Ho Seong KIM
Annals of Pediatric Endocrinology & Metabolism 2019;24(4):248-252
Autoimmune polyendocrine syndrome type 1 (APS-1), or autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy is a rare, autosomal recessive autoimmune disease caused by a mutation of the autoimmune regulator (AIRE) gene. The main symptom triad in APS-1 comprises chronic mucocutaneous candidiasis, adrenal insufficiency, and hypoparathyroidism. Various autoimmune diseases and ectodermal abnormalities are also commonly associated with the syndrome. The treatment of APS-1 includes hormone replacement and symptom control. It is important to monitor such patients for clinical manifestations of their disease through regular follow-up. We report the case of a 10-year-old Korean girl with APS-1 due to a novel compound heterozygous mutation of the AIRE gene. This patient's main clinical manifestations were adrenal insufficiency and chronic mucocutaneous candidiasis. The patient had a previously known pathogenic variant of c.1513delG (p.Ala505ProfsTer16), and a newly discovered variant of c.1360dupC (p.His454ProfsTer50).
Adrenal Insufficiency
;
Autoimmune Diseases
;
Candidiasis, Chronic Mucocutaneous
;
Child
;
Ectoderm
;
Female
;
Follow-Up Studies
;
Humans
;
Hypoparathyroidism
;
Polyendocrinopathies, Autoimmune
9.Trend Analysis of Research Articles Published in the Korean Journal of Women Health Nursing from 2013 to 2017.
Young Jin LEE ; Seo Yun KIM ; Saem Yi KANG ; Yoo Jeong KANG ; Lan JIN ; Hee Yoen JUNG ; Hae Won KIM
Korean Journal of Women Health Nursing 2018;24(1):90-103
PURPOSE: To analyze articles published in the Korean Journal of Women Health Nursing from 2013 to 2017 to determine the latest research trends and understand how 2013 Korea Women's Health Statistics were reflected in journal articles. METHODS: A total of 130 studies were analyzed. Research design, types of research, research framework, research subjects, characteristics of quantitative research, characteristics of qualitative research, and keywords were analyzed using a structured analysis format. RESULTS: Quantitative and qualitative research accounted for 83.8% and 13% of these 130 studies analyzed, respectively. Non-experimental and experimental research accounted for 70.7% and 13.1% of these studies, respectively. The most frequent study subjects were childbearing women (62.8%), including college students, mothers, and adults. A total of 69.1% of non-experimental research and 88.2% of experimental research used convenience sampling. Questionnaires were most frequently used for data collection. The most frequent keyword domain involved health-related concepts (41%) among nine domains and the most frequently used keyword was “women.” CONCLUSION: This study suggest that further experimental research should be conducted in the future. Also, adolescent and the elderly women should be focused on as subjects in future studies based on results of 2013 Korean Women's Health Statistics.
Adolescent
;
Adult
;
Aged
;
Data Collection
;
Female
;
Humans
;
Korea
;
Mothers
;
Nursing*
;
Qualitative Research
;
Research Design
;
Research Subjects
;
Women's Health
10.Campylobacter jejuni Bacteremia in a Liver Cirrhosis Patient and Review of Literature: A Case Study.
Jin Gu YOON ; Saem Na LEE ; Hak Jun HYUN ; Min Joo CHOI ; Ji Ho JEON ; Eunju JUNG ; Seonghui KANG ; Jeeyong KIM ; Ji Yun NOH ; Won Suk CHOI ; Joon Young SONG ; Hee Jin CHEONG ; Woo Joo KIM
Infection and Chemotherapy 2017;49(3):230-235
Campylobacter infection causes gastrointestinal symptoms such as abdominal pain or diarrhea. Occasionally, Campylobacter bacteremia affects immunocompromised patients; however, serious outcomes are known to be rare. Here, we present a case of a patient with Campylobacter bacteremia who had underlying liver cirrhosis. The patient had fever and diarrhea. These symptoms subsided after treatment with cefotaxime. Campylobacter jejuni was isolated in the blood culture after 10 days. In addition, previously reported cases of Campylobacter bacteremia in Asian countries were reviewed with respect to antimicrobial sensitivities.
Abdominal Pain
;
Asian Continental Ancestry Group
;
Bacteremia*
;
Campylobacter Infections
;
Campylobacter jejuni*
;
Campylobacter*
;
Cefotaxime
;
Diarrhea
;
Fever
;
Humans
;
Immunocompromised Host
;
Liver Cirrhosis*
;
Liver*

Result Analysis
Print
Save
E-mail